Finding Hope in Treatment: New Developments in MPN Research 2023

Interview with MPN expert, Dr. Srdan Verstovsek, Patients are Asking Episode 3 from ASH 2022. Learn about an exciting new anti-mutant calreticulin (CALR) targeted monoclonal antibody that may lead to a molecular response in MF and ET.

What were some of the highlights of the American Society of Hematology (ASH) conference and what treatment can patients look forward to in the year ahead?

Is the level of fibrosis a reliable marker in myelofibrosis?

Are all of our MPN symptoms disease related or might there be other causes?
Be the first to comment